Five Potential Blockbuster Oncology Approvals To Look Out For In 2023

With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.    

Piggy Money
These Pipeline Drugs Could Exceed $1bn In Sales • Source: Shutterstock

One of three CD20 X CD3 bispecific antibody candidates striving for a 2023 thumbs up in late-stage diffuse large B-cell lymphoma (DLBCL), Genmab A/S and partner AbbVie Inc.’s epcoritamab is set to be filed in the EU later this year. The firms are also preparing for a US filing in large B-cell lymphoma. 

While chimeric antigen receptor (CAR) T-cell drugs such as Kite Pharma’s Yescarta (axicabtagene ciloleucel) have recently won approval in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.